Novartis is set to take on Roche and Regeneron in wet age-related macular degeneration (AMD) with its latest FDA approval for Beovu. In the pharmacy benefit, Roche’s Lucentis holds preferred status for just 2% of covered lives, growing to 18% with prior authorization and/or step therapy. Eylea is also preferred for 2% of lives, growing to 20% with prior authorization and/or step therapy. In the medical benefit, Lucentis is covered for 37% of insured lives, with Eylea at 29%.

SOURCE: MMIT Analytics, as of 10/9/19